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A safe and effective Hantaan virus (HTNV) vaccine is highly desirable because HTNV
causes an acute and often fatal disease (hemorrhagic fever with renal syndrome,
HFRS). Since the immunity of the inactivated vaccine is weak and the safety is poor,
HTNV virus-like particles (VLPs) offer an attractive and safe alternative. These particles
lack the viral genome but are perceived by the immune system as virus particles.
We hypothesized that adding immunostimulatory signals to VLPs would enhance their
efficacy. To accomplish this enhancement, we generated chimeric HTNV VLPs containing
glycosylphosphatidylinositol (GPI)-anchored granulocyte macrophage colony-stimulating
factor (GM-CSF) or CD40 ligand (CD40L) and investigated their biological activity in
vitro. The immunization of mice with chimeric HTNV VLPs containing GM-CSF or CD40L
induced stronger humoral immune responses and cellular immune responses compared
to the HTNV VLPs and Chinese commercial inactivated hantavirus vaccine. Chimeric
HTNV VLPs containing GM-CSF or CD40L also protected mice from an HTNV challenge.
Altogether, our results suggest that anchoring immunostimulatory molecules into HTNV
VLPs can be a potential approach for the control and prevention of HFRS.
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INTRODUCTION
Hantaan virus (HTNV) belongs to theHantavirus genus of the Bunyaviridae family and is a rodent-
borne, enveloped RNA virus that is composed of three single-stranded RNA segments, L (large), M
(medium), and S (small), that encode an RNA polymerase, the glycoproteins (GPs) Gn and Gc, and
a nucleocapsid protein (NP), respectively, (Schmaljohn and Hjelle, 1997; Khaiboullina et al., 2005).
HTNV causes a febrile illness in humans, namely, hemorrhagic fever with renal syndrome (HFRS).
There are more than 100,000 cases per year, primarily in Asia, with a case-fatality rate of 10–15%
(Zeier et al., 2005; Hooper et al., 2006).
Given the severe clinical complications and widespread geographical distribution of the HTNV
infection, the prevention of this infection has been one of the major concerns in the public health
field. Because there are no drugs against the HTNV infection, vaccination remains the most
desirable option for disease prevention. Inactivated vaccines have contributed to a steady drop in
hospital admissions for HFRS (Schmaljohn, 2009). Nevertheless, inactivated vaccines seldom elicit
protective cellular responses despite its neutralizing activity, and there are no studies reporting
that it could establish long-term memory immunity (Zhang et al., 2007; Song et al., 2016). Safety
is another major obstacle of inactivated vaccines because it may contain some infectious particles.
Cheng et al. Research on Chimeric HTNV VLPs
Therefore, approaches to HTNV vaccine development that
are based on recombinant vectors, recombinant proteins, or
multiprotein assemblies, such as virus-like particles (VLPs), have
been proposed (Kamrud et al., 1999; Li et al., 2007, 2010, 2012,
2013).
Many viral structural proteins, including HTNV, have the
intrinsic ability to assemble into VLPs that are similar in size
to viruses but lack the viral genetic materials. Some VLP-
based vaccines have already been licensed and commercialized.
The prophylactic human vaccines against hepatitis B virus
(HBV) and human papilloma virus (HPV), both based on VLPs
derived from these viruses, have been FDA-approved and are
in use. Additionally, other VLP vaccines are currently under
investigation for several families of human viruses, including
human immunodeficiency virus, hepatitis virus, rotavirus,
parvovirus and influenza virus (Takehara et al., 1988; Conner
et al., 1996; Tsao et al., 1996; Quan et al., 2007; Wang et al., 2007;
Kang et al., 2009; Klausberger et al., 2014). Several studies have
demonstrated the induction of neutralizing antibodies via HTNV
VLP immunization usingmousemodels (Betenbaugh et al., 1995;
Li et al., 2010). Importantly, VLP antigens can be processed
to present antigens through the major histocompatibility class
(MHC) II exogenous pathway and the MHC I endogenous
pathway, inducing both CD4+ and CD8+ T cell-mediated
immune responses (Bachmann et al., 1996; Reimann and
Schirmbeck, 1999).
Although, VLPs are a promising strategy for HTNV vaccines,
developing approaches to enhance the immunogenicity of
VLPs is highly desirable. It has been reported that a large
variety of active molecules can be attached to the VLP
surface (Zdanowicz and Chroboczek, 2016). The present study
investigated the hypothesis that immunostimulatory molecules
can be incorporated into HTNV VLPs to increase their efficacy.
Granulocyte-macrophage colony-stimulating factor (GM-
CSF) is a secreted protein. It could be easily incorporated
into HTNV VLPs to form chimeric VLPs (HTNV VLP-
GM-CSF) with the help of the membrane-anchored protein
glycosylphosphatidylinositol (GPI). Thus, a GPI-anchored form
of GM-CSF was expressed in the present study. GM-CSF
is known to expand myeloid-derived dendritic cell (DC)
populations to augment antigen-induced humoral and cellular
immune responses and affect Th1/Th2 cytokine balance. GM-
CSF has been extensively used as an effective genetic and protein
adjuvant to enhance the immunogenicity of tumor and vaccine
antigens (Disis et al., 1996; Kass et al., 2001; Poloso et al., 2002;
Skountzou et al., 2007; Chou et al., 2010).
Another immunostimulatory molecule is the CD40 ligand
(CD40L), which is a surface molecule and has a membrane-
binding region; therefore it could easily be incorporated into
HTNV VLPs to form chimeric VLPs (HTNV VLP-CD40L).
CD40L is primarily expressed on mature CD4+ T cells. The
interaction between CD40L and CD40 is important for T cell-
dependent B cell activation and isotype switching. The binding
of CD40L to CD40 modulates cellular immune responses by
inducing the expression of costimulatory molecules that reside
on antigen-presenting cells (APCs). Because of the upregulation
of costimulatory molecules, APCs are activated, CD4+ T cell
responses are augmented by increased cytokine production,
and CD4+-dependent naive CD8+ T cells are activated in vivo
(Skountzou et al., 2007; Lin et al., 2009; Zhang et al., 2010).
In the present study, we incorporated GPI-anchored forms
of either GM-CSF or CD40L into HTNV VLPs to produce
chimeric VLPs (HTNV VLP-GM-CSF, HTNV VLP-CD40L).
The immune responses to these chimeric VLPs and the
biological effects of these particles on immune system cells were
investigated.
MATERIALS AND METHODS
Animals
Adult female C57BL/6 mice (8 weeks old) were purchased
from the animal research center of the Fourth Military Medical
University (Xi’an, China). The mice were housed in isolated and
ventilated cages. All experiments were performed in accordance
with protocols approved by the Fourth Military Medical
University Medical Ethics Committee (Xi’an, Shaanxi, China;
approval no. XJYYLL-2014508). The animals were acclimated
to the laboratory environment for 5–7 d before use. While in
their home cage environment, the animals were allowed free
access to a standard animal diet and tap water. The room was
maintained at 20–23◦C with a 12 h/12 h light/dark cycle. The
animals were deeply anesthetized using inhaled isoflurane (1–
3% or as needed) before all operations. All efforts were made
to minimize animal suffering, to reduce the number of animals
used and utilize alternatives to in vivo experiments whenever
appropriate or feasible.
Viruses and Cells
HTNV strain 76–118 was provided by our library (Cheng et al.,
2014). The pFastBacTM Dual expression system, which includes
the pFastBacTM Dual vector, was purchased from Invitrogen
(Carlsbad, CA, USA). Sf9 insect cells (ATCC, Rockville, MD,
USA), used for packaging and propagating the recombinant
baculoviruses (rBVs; Palomares et al., 2012), were maintained
in Sf-900 II serum-free medium (SFM; Gibco, Grand Island,
NY, USA). Vero E6 cells (ATCC, Rockville, MD, USA) used
for the cellular microculture neutralization test and target cell
establishment for the CTL assay were maintained in RPMI-1640
medium (Invitrogen, Carlsbad, CA, USA) that was supplemented
with 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA).
Antibodies
Monoclonal antibodies (mAb) 1A8 (specific to the HTNV NP;
Xu et al., 2002), Gn-4 (specific to the HTNV Gn), Gc-10
(specific to the HTNV Gc), and 3G1 (with high neutralizing
Ab activity against HTNV) were prepared in our laboratory.
Our laboratory also supplied the mAb Sp2/0 (Cheng et al.,
2014; negative control). Rat anti-mouse GM-CSF and rabbit
anti-mouse CD40L antibodies were purchased from Abcam
(Cambridge, MA, USA). Other secondary antibodies, including
FITC-conjugated antibodies, Cy3-conjugated antibodies, HRP-
conjugated antibodies, and PE-conjugated antibodies were
purchased from eBioscience (San Diego, CA, USA).
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Protein
The following protein antigens were used for the enzyme-
linked immunospot (ELISPOT) assay and enzyme-linked
immunosorbent assay (ELISA): (i) purified HTNV GP was
obtained from the Biological Product Academy (Lanzhou,
Gansu, China), and (ii) HTNV NP was expressed and purified
by our laboratory. Soluble recombinant murine GM-CSF and
CD40L were purchased from PeproTech (Rocky Hill, NJ, USA)
for the in vitro cultures.
Generation of HTNV VLP and Chimeric
HTNV VLPs
DNA Constructs
Plasmids containing cDNAs encoding M, S, mouse GPI-GM-
CSF, and mouse CD40L were synthesized by TaKaRa (Dalian,
Liaoning, China) and then digested with EcoRI and NotI to
obtain DNA fragments of M, S, GM-CSF, and CD40L. Next,
these fragments were ligated into pFastBacTM Dual vectors
with the polyhedrin (polh) promoter. All recombinant DNA
constructs were confirmed by restriction enzyme digestion
and by DNA sequencing and subsequently transformed into
Escherichia coli DH10BacTM cells to isolate recombinant
bacmids. All recombinant bacmids were confirmed by PCR
amplification using the following primers: pUC/M13 (forward)
5′-CCCAGTCACGACGTTGTAAAACG-3′ and pUC/M13
(reverse) 5′-AGCGGATA ACAATTTCACACAGG-3′. Then,
the recombinant bacmids were transfected into Sf9 insect cells
using Cellfectin R© II Reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions to produce rBVs
(rBV-M, rBV-S, rBV-GM-CSF, and rBV-CD40L). The rBV titers
were determined using a viral plaque assay according to the
manufacturer’s instructions. The plaque was used to purify
the rBVs.
Target Protein Expression in Sf9 Insect Cells
The infected Sf9 insect cells were harvested after 48 h,
resuspended in 0.01M PBS (pH 8.0) and prepared as a
monolayer on glass slides by acetone fixation to determine
the rBV expression (rBV-M, rBV-S, rBV-GM-CSF, and rBV-
CD40L). For GP, either mAb Gn-4 or Gc-10 was mixed with
rBV-M infected cells and incubated at 4◦C for 30min. As a
secondary antibody, FITC-conjugated goat anti-mouse antibody
was incubated at 4◦C for 30min. For NP, mAb 1A8 was
mixed with rBV-S infected cells and incubated at 4◦C for
30min. As a secondary antibody, FITC-conjugated goat anti-
mouse antibody was incubated at 4◦C for 30min. For GM-
CSF, a rat anti-mouse GM-CSF antibody was mixed with rBV-
GM-CSF infected cells and incubated at 4◦C for 30min. As
a secondary antibody, FITC-conjugated goat anti-rat antibody
was incubated at 4◦C for 30min. For CD40L, a rabbit anti-
mouse CD40L antibody was mixed with rBV-CD40L infected
cells and incubated at 4◦C for 30min. As a secondary antibody,
FITC-conjugated goat anti-rabbit antibody was incubated at
4◦C for 30min. After staining, the cells were analyzed with
fluorescence microscopy using an Olympus IX71 microscope
(Tokyo, Japan).
Production and Purification of HTNV VLP and
Chimeric HTNV VLPs
Sf9 insect cells were coinfected with rBV-M (10 PFU/cell) and
rBV-S (10 PFU/cell) at a multiplicity of infection (MOI) ratio
of 1:1 and incubated at 27◦C for 72 h to produce HTNV
VLPs. HTNV VLP-GM-CSF was produced from Sf9 cells that
were coinfected with rBV-M (4 PFU/cell), rBV-S (4 PFU/cell),
and rBV-GM-CSF (12 PFU/cell) at an MOI ratio of 1:1:3.
HTNV VLP-CD40L was produced from Sf9 cells that were
coinfected with rBV-M (4 PFU/cell), rBV-S (4 PFU/cell), and
rBV-CD40L (12 PFU/cell) at an MOI ratio of 1:1:3. Three
days post infection, the culture supernatants were collected,
centrifuged at 1000 rpm for 20min and filtered through a 0.45
µm pore-size filter. Next, the VLPs were initially concentrated
via ultrafiltration using a 15-ml centrifugal filter with a 3 kDa
cutoff (Millipore, Billerica, MA, USA) at 3000 rpm for 2 h at
4◦C in a Thermo Scientific 75003608 Rotor (Waltham, MA,
USA). Then, the VLPs were further purified through a 20–
60% discontinuous sucrose gradient at 38,000 rpm for 18 h
at 4◦C in a Beckman SW 41 Ti Rotor (Fullerton, CA, USA).
The VLP bands were collected, washed with PBS, pelleted and
resuspended overnight in PBS. The protein concentration of each
sample was estimated using a Bio-Rad protein assay (Bio-Rad
Laboratories, Hercules, CA, USA) to quantify the purified VLP
yield.
Identification of HTNV VLP and Chimeric
HTNV VLPs
Confocal Laser Scanning Microscope
Sf9 insect cells coinfected with rBV-M, rBV-S, and rBV-GM-CSF
or rBV-CD40L were harvested and prepared as a monolayer on
glass slides to determine the expression and cellular localization
of the proteins that form the components of the VLPs. For GP,
mAb Gn-4 was mixed with infected cells and incubated at 4◦C
for 30min. As a secondary antibody, FITC-conjugated goat anti-
mouse antibody was incubated at 4◦C for 30min. For GM-CSF,
a rat anti-mouse GM-CSF antibody was mixed with infected
cells and incubated at 4◦C for 30min. As a secondary antibody,
Cy3-conjugated goat anti-rat antibody was incubated at 4◦C for
30min. For CD40L, a rabbit anti-mouse CD40L antibody was
mixed with infected cells and incubated at 4◦C for 30min. As
a secondary antibody, Cy3-conjugated goat anti-rabbit antibody
was incubated at 4◦C for 30min. After being stained, the cells
were analyzed with a confocal laser-scanning microscope using
an Olympus FV1000 microscope (Tokyo, Japan).
SDS-PAGE and Western-Blot
Samples from purified VLPs were lysed in 2× loading buffer
(0.08M Tris [pH 6.8], with 2.0% SDS, 10% glycerol, 0.1M
dithiothreitol, and 0.2% bromophenol blue) and boiled for 5min
for protein analysis. All samples were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
with identical concentrations (5 or 10 µg). HTNV GP, NP, GM-
CSF, and CD40L were probed using mAbs Gn-4/Gc-10, 1A8, rat
anti-mouse GM-CSF, and rabbit anti-mouse CD40L antibodies,
respectively.
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Electron Microscopy
Sf9 cells coinfected with rBVs were fixed in 0.25% glutaraldehyde
and 1% osmium tetraoxide, dehydrated with ethanol, and then
embedded in Epon resin to examine VLP production. Thin
sections were stained with lead citrate and uranyl acetate and
observed using electronmicroscopy. Samples from purified VLPs
were applied to the carbon-coated Formvar grids for 1min. The
grids were then immediately stained with 1% phosphotungstic
acid for 1 min and examined using a transmission electron
microscope.
Immunoelectron Microscopy
Purified HTNV VLP-GM-CSF and HTNV VLP-CD40L were
detected by immunoelectron microscopy to determine whether
the targeted molecules (GM-CSF and CD40L) were efficiently
incorporated into the HTNV VLPs. Samples were absorbed
onto freshly glow-discharged, carbon- and Formvar-coated, 300-
mesh nickel grids for 2 min. The VLPs were stained using
anti-GM-CSF and anti-CD40L antibodies, and a secondary
antibody labeled with 10 nm colloidal gold. Then, the grids were
immediately stained with 1% phosphotungstic acid for 1min, and
examined using a transmission electron microscope.
Coimmunoprecipitation
Samples from purified HTNV VLP-GM-CSF and HTNV
VLP-CD40L were immunoprecipitated with anti-GM-CSF and
anti-CD40L antibodies, respectively, subjected to SDS-PAGE,
and probed with mAb Gn-4 to determine whether the
targeted molecules (GM-CSF and CD40L) were efficiently
incorporated into the HTNV VLPs. The samples from the
purified HTNV VLP-GM-CSF and HTNV VLP-CD40L were
also immunoprecipitated with Gn-4, subjected to SDS-PAGE,
and probed with anti-GM-CSF and anti-CD40L antibodies,
respectively.
Functional Characterization of HTNV VLP
and Chimeric HTNV VLPs
Bone Marrow Cell Proliferation
Mouse bone marrow cells were labeled with CFSE
(carboxyfluorescein diacetate succinimidyl ester; Molecular
Probes, Eugene, OR, USA) at a final concentration of 1 µM.
CFSE was quenched by further incubation in serum-containing
medium and extensively washed in RPMI medium. The CFSE-
labeled bone marrow cells were cultured in RPMI medium in
the presence of 20 µg/µl of VLPs to determine the effect of
chimeric VLPs on cell proliferation. After incubation at 37◦C
in 5% CO2 for 4 d, the cells were harvested and analyzed by
fluorescence-activated cell sorting using a Beckman Epics XL
instrument (Fullerton, CA, USA). This experiment was repeated
four times.
Bone Marrow Cell Differentiation
The bone marrow cultures that were expanded in the presence
of VLPs for 4 d were stained with PE-conjugated anti-CD11c and
FITC-conjugated anti-CD11b for 1 h at 4◦C, fixed in PBS with
1.5% paraformaldehyde, and analyzed using a Beckman Epics XL
instrument to evaluate the cell differentiation. This experiment
was repeated four times.
B Cell Activation
The mouse spleen cells were cultured in RPMI medium in the
presence of 20 µg/µl of VLPs to analyze the phenotypes of the
activated cells. After incubation at 37◦C in 5% CO2 for 4 d, one
million cells were stained with PE-conjugated anti-CD69 and
FITC-conjugated anti-B220 for 20min at 4◦C. After staining, the
cells were washed and fixed in PBS with 1% paraformaldehyde
and analyzed using a Beckman Epics XL instrument. This
experiment was repeated four times.
Immunizations
The female C57BL/6 mice were divided into seven groups.
Eight mice were assigned to each group (five experimental and
two control groups). The first three experimental groups were
injected subcutaneously with 200 µl (100 µg) of either purified
HTNV VLPs (VLP) or chimeric VLPs (VLP-GM-CSF, VLP-
CD40L) per mouse. The other two experimental groups were
injected subcutaneously with 200 µl (100 µg) of purified HTNV
VLP and 5 µg of soluble recombinant GM-CSF or CD40L per
mouse (VLP+GM-CSF, VLP+CD40L). The two control groups
were immunized with either 200 µl (100 µg) of commercially
purchased inactivated Hantavirus vaccine (Vaccine; Tianyuan,
Hangzhou, Zhejiang, China) or with 200 µl of PBS (naive) per
mouse. All immunizations were administered three times at 2
week intervals. The mouse (four mice per group) sera were
collected individually via retro-orbital plexus puncture 10 d after
the last immunization. Additionally, splenocytes were isolated for
subsequent assays.
Characterization of the Effect on DCs
In vivo
DC Proliferation
Splenocytes from the C57BL/6 mice (four mice per group) were
isolated 10 d after the last immunization. The numbers of DCs
were counted by gating CD11c and SSC. A total of 100,000 events
per sample of splenocytes were collected for each analysis.
DC Activation
One million splenocytes freshly isolated from the immunized
mice (four mice per group) were washed twice with PBS and were
stained with PE-conjugated anti-CD86 and FITC-conjugated
anti-CD40 for 20min at 4◦C. After staining, the cells were washed
and fixed in PBS with 1% paraformaldehyde and analyzed using
a Beckman Epics XL instrument. The surface marker expression
levels of DCs, CD40, and CD86, were analyzed to evaluate their
degree of activation.
DC Types
Freshly isolated splenocytes collected from the immunized mice
(four mice per group) were used to analyze the types of DCs.
After washing, the splenocytes were stained with antibodies
against surface markers with PerCP/Cy5.5-conjugated anti-
CD8a, PE-conjugated anti-CD11b, and FITC-conjugated anti-
CD40 for 40min at 4◦C. After staining, the cells were washed
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and fixed in PBS with 1% paraformaldehyde and analyzed using
a Beckman Epics XL instrument. The surface marker expression
levels of DCs, CD8a, CD11b, and CD11c were analyzed to
determine their type.
Evaluation of Humoral and Cellular
Immune Responses
Detection of HTNV NP- and GP-Specific Antibodies
HTNV NP- and GP-specific antibody titers were determined
using indirect ELISA. Purified NP and GP were used as coating
antigens. Serial dilutions of sera from immunizedmice (fourmice
per group) with an initial dilution of 1:10 were added to the plates
and reacted with either NP or GP. The positive controls consisted
of 1:100 dilutions of mAbs 1A8 and Gn-4. A 1:1000 dilution of
mAb Sp2/0 was used as the negative control. HRP-conjugated
goat anti-mouse antibody was used for detection. The absorbance
was measured at a wavelength of 450 nm using a Synergy HT
ELISA plate reader (Biotec, Dresden, Germany). An absorbance
>0.1 and a positive/negative (P/N) value > 2.1 was considered
significant. The antibody titers were defined as the reciprocal
of the serum dilution with the highest positive response. The
geometric mean titer (GMT) was utilized to compare specific
antibody titers among all groups.
Microneutralization Test
The cell microculture neutralization test was performed on
monolayers of Vero E6 cells grown in a 96-well tissue culture
plate with the HTNV 76–118 strain. Cells that were grown in
RPMI-1640 medium supplemented with 10% FBS were plated
at a density of 2 × 104 cells per well and cultured for 18–24 h
before testing. The sera from the immunized mice (four mice per
group) were filtered through 0.22 µm filters, then diluted serially
two-fold from an initial 1:10 dilution in RPMI-1640 medium
containing 2% FBS, and combined with an equal volume of 100
TCID50 HTNV (76–118 strain). After 90min, the mixture was
transferred to monolayers of Vero E6 cells and incubated at 37◦C
for 7 d in a 5% CO2 incubator. Thereafter, the cells were lysed by
three consecutive freeze-thaw cycles. HTNV antigens in the cell
lysates were detected using sandwich ELISA. The mAb 1A8 was
used as a coating antibody, and HRP-conjugated 1A8 was used
as the detecting antibody. The mAb 3G1 and Sp2/0 were used as
positive and negative controls, respectively. The absorbance was
measured at a wavelength of 450 nm using a Synergy HT ELISA
plate reader. The neutralizing antibody titer was defined as the
maximum dilution of serum that inhibited HTNV infection in
50% of the cells.
Detection of Cytokines Secreted by T cells
The ELISPOT assay was used to determine the frequency of
responding T cells that were capable of secreting IFN-γ upon
stimulation. The mice were sacrificed 10 d after the final booster
immunization. The spleen cells from the immunized mice
(four mice per group) were purified in lymphocyte separation
medium. CD4+ or CD8+ T cells from splenocytes were depleted
using anti-CD4-coated Dynabeads (Invitrogen Dynal AS, Oslo,
Norway) or anti-CD8-coated Dynabeads (Invitrogen Dynal AS,
Oslo, Norway). The isolated T cells (1 × 106 cells in 100
µl) were added to each well of pre-coated IFN-γ microtiter
plates (Mabtech, Stockholm, Sweden), and stimulated with a
mixture of HTNV purified GP and NP (10 µg/ml) or with
the positive mitogenic stimulator concanavalin A (ConA, 4
µg/ml). The isolated T cells incubated with 100 µl of 2% FBS
supplemented RPMI-1640 medium were used as negative or
background controls. These plates were incubated at 37◦C for 18
h. Cytokine ELISPOT development was performed according to
the manufacturer’s instructions. The spots were counted using an
ELISPOT reader system (AID, Strasberg, Germany). The results
were expressed as the mean number of specific IFN-γ spot-
forming cells per 1 × 106 splenocytes. The assays for IL-2, IL-4,
and IL-10 secretion were similar to those described for IFN-γ.
Cytotoxicity Assay
A CytoTox 96TM nonradioactive cytotoxicity assay kit (Promega,
Madison, WI, USA) was used according to the manufacturer’s
instructions to detect the level of specific toxicity in response
to the Vero E6 cells (target cells) infected with the HTNV 76–
118 strain. The target cells were plated onto 96-well U-bottomed
microtiter plates at 1 × 104 cells per well and a volume of 50 µl.
The splenocytes from the immunized mice (four mice per group;
effector cells) were prepared as described above and added to a
final volume of 50 µl with effector/target (E/T) ratios of 100:1,
50:1, and 20:1. Normal splenocytes were added as a negative
control. The assay plate included the following cells as controls:
spontaneous lactate dehydrogenase (LDH) release from effector
cells (50 µl of target cells and 50 µl of 5% FBS RPMI-1640
medium), spontaneous LDH release from target cells (50 µl of
target cells and 50µl of 5% FBS RPMI-1640 medium), maximum
LDH release from target cells (50 µl of target cells, 50 µl of
5% FBS RPMI-1640 medium, and 10 µl of the lysis solution),
a volume correction control (100 µl of 5% FBS RPMI-1640
medium and 10 µl of the lysis solution), and a culture medium
background control (100 µl of 5% FBS RPMI-1640 medium).
The percentage of Vero E6 cell lysis was calculated according to
the following formula: % cytotoxicity = [(E − St − Se)/(M −
St)] × 100 (E, LDH release from effector-target co-culture cells;
St, spontaneous LDH release from target cells; Se, spontaneous
LDH release from effector cells; M, maximum LDH release from
target cells).
Animal Protection Experiments
Ten days after the final booster immunization, the C57BL/6 mice
(four mice per group) were infected with the HTNV 76–118
strain (1× 105 pfu/mouse) by intramuscular injection. Then, the
mice were killed after 3 d, and the major tissues, including the
cerebrum, heart, liver, spleen, lungs, and kidneys, were collected
individually for subsequent assays.
Detection of HTNV Antigens in the Tissues by ELISA
The tissue samples from the HTNV-infected mice (four mice per
group) were weighed, diluted in PBS, and then freeze-thawed
(−80/37◦C) three times after being ground to prepare 10%
(g/ml) tissue suspensions. The samples were centrifuged at 12,000
rpm for 30min at 4◦C, and the supernatants were collected.
The HTNV antigens in the supernatants were detected using
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sandwich ELISA. The mAb 1A8 was used as a coating antibody,
and HRP-conjugated 1A8 was used as the detecting antibody.
The normal tissue supernatants were used as negative controls.
The absorbance was measured at a wavelength of 450 nm using
a Synergy HT ELISA plate reader. An OD450 value exceeding
2.1-fold of the negative controls was considered a positive result.
Detection of HTNV Nucleic Acids in Tissues by
qRT-PCR
The total cellular RNAs in the tissue samples from the
HTNV-infected mice (four mice per group) were extracted
using an RNAprep Pure Tissue Kit (Tiangen, Beijing, China).
Then, 1 µg of total cellular RNA from each sample was
amplified using a SYBR Premix Ex Taq II Kit and the
following HTNV RNA-specific primers: HTNV (forward) 5′-
GATCAGTCACAGTCTAGTCA-3′ and HTNV (reverse) 5′-
TGATTCTTCCACCATTTTGT-3′. GAPDH was included in the
qRT-PCR as an internal control for cellular RNA using the
following mouse GAPDH-specific primers: GAPDH (forward)
5′-AGGCCGGTGCTGAGTATG TC-3′ and GAPDH (reverse)
5′-TGCCTGCTTCACCACCTTCT-3′.
Statistical Analysis
All data were expressed as the mean ± the standard error of
mean (SEM) and are representative of at least two independent
experiments. The Student’s t-test was used to determine
significant differences between the paired experimental and
control groups. One-way ANOVA was used to determine
statistically significant differences among the experimental
groups. A p-value of 0.05 or less was considered significant.
RESULTS
HTNV VLP and Chimeric HTNV VLPs Were
Produced and Purified Successfully
To express HTNV GP and NP, GM-CSF and CD40L in Sf9 insect
cells, first, we cloned these genes into baculovirus shuttle vectors
and produced rBVs. Then, we confirmed the expression of GP,
NP, GM-CSF, and CD40L by infecting Sf9 insect cells with the
rBVs and by analyzing these cells using an immunofluorescence
assay (IFA). All the target proteins were expressed in Sf9 insect
cells (Figure 1). HTNV VLPs were produced by Sf9 insect cells
coinfected with rBV-M and rBV-S. HTNV VLP-GM-CSF was
produced by Sf9 insect cells coinfected with rBV-M, rBV-S,
and rBV-GM-CSF and HTNV VLP-CD40L was produced by
Sf9 insect cells coinfected with rBV-M, rBV-S, and rBV-CD40L.
Then, the VLPs were harvested from the culture supernatants
and purified using sucrose gradient ultracentrifugation. The BCA
Protein Assay Kit was used to measure the VLP concentration
after purification via sucrose gradient ultracentrifugation. The
concentration of HTNV VLPs, VLP-CD40L, and VLP- GM-CSF
reached up to 3.648, 3.824, and 3.301 mg/ml, respectively.
We determined the expression and cellular localization of the
proteins forming the VLP components in the Sf9 insect cells.
We could detect the expression of HTNV GP and CD40L in the
same Sf9 insect cells coinfected with rBV-M, rBV-S, and rBV-
CD40L (Figure 2A). Similarly, we could detect the expression of
HTNV GP and GM-CSF in the same Sf9 insect cells coinfected
with rBV-M, rBV-S, and rBV-GM-CSF (Figure 2C). Normal
Sf9 insect cells were used as negative control (Figures 2B,D).
We also collected cells coinfected with rBVs to detect VLP
production using electron microscopy; the particle sizes ranged
from ∼100 nm in diameter (Figures 3A–C). The purified VLPs
were routinely tested for integrity and homogeneity using
electron microscopy; the particle sizes ranged from ∼100 nm
in diameter (Figures 3D–F). The VLPs were also analyzed using
SDS-PAGE and Western blot. The results of the SDS-PAGE
analysis indicated that all the VLPs exhibited three Coomassie-
stained bands at apparent molecular weights of ∼72, 55, and
50 kDa and that HTNV VLP-GM-CSF and HTNV VLP-CD40L
also showed a 29 and 37 kDa band (Figure 4A), which were
similar to the molecular weights of Gn, Gc, NP, GM-CSF, and
CD40L, respectively. Western blot analysis indicated that Gn, Gc,
and NP from all the purified VLPs were detected by mAbs Gn-
4, Gc-10, and 1A8, respectively (Figures 4B–D). This analysis
also showed that GM-CSF and CD40L from the purified HTNV
VLP-GM-CSF and HTNVVLP-CD40L were detected by rat anti-
mouse GM-CSF and by rabbit anti-mouse CD40L antibodies,
respectively (Figures 4E,F).
We used immunoelectron microscopy to determine
whether GM-CSF and CD40L were directly incorporated
into the HTNV VLPs. The particle sizes were ∼100 nm in
diameter, and the colloidal gold could be detected around the
particles (Figures 5A,B). The immunoelectron microscopy
results confirmed that the GM-CSF and CD40L were
directly incorporated into the HTNV VLPs. We also used
a coimmunoprecipitation assay to determine whether GM-
CSF and CD40L were directly incorporated into the HTNV
VLPs. HTNV VLP-GM-CSF was immunoprecipitated with
rat anti-mouse GM-CSF antibody, and the proteins were
probed with Gn-4 mAb after separation by SDS-PAGE. HTNV
GP coprecipitated, indicating that GM-CSF and HTNV
GP were present in the same VLP structures (Figure 6A).
Similarly, GM-CSF coprecipitated when HTNV VLP-GM-
CSF was first immunoprecipitated with the anti-GP antibody
(Gn-4) and the blots were subsequently probed with rat
anti-mouse GM-CSF (Figure 6B). Analogous experiments
confirmed the incorporation of CD40L into the HTNV VLPs
(Figures 6C,D).
Taken together, these results demonstrate that HTNV
VLPs and chimeric HTNV VLPs were produced and purified
successfully.
GM-CSF and CD40L Incorporated into
HTNV VLPs Maintained Their Biological
Activities
GM-CSF is a potent activator that induces the proliferation and
differentiation of bone marrow cells. GM-CSF and CD40L also
induce the activation of splenic B cells. First, we tested whether
these VLPs could induce the proliferation of bone marrow
cells to determine whether GM-CSF and CD40L incorporated
into HTNV VLPs maintained their endogenous activities. We
labeled bone marrow cells with 1 µM CFSE and incubated
the cells for 4 d in the presence of 20 µg/ml of VLPs.
As expected, we found that HTNV VLP-GM-CSF effectively
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FIGURE 1 | The IFA of GP, NP, GM-CSF, and CD40L expression in Sf9 insect cells. (A) HTNV GP expression was detected using mAb Gn-4 (Gn-specific) in Sf9
insect cells infected with rBV-M. (B) HTNV GP expression was detected using mAb Gc-10 (Gc-specific) in Sf9 insect cells infected with rBV-M. (C) HTNV NP
expression was detected using mAb 1A8 (NP-specific) in Sf9 insect cells infected with rBV-S. (D) GM-CSF expression was detected using rat anti-mouse GM-CSF
antibody in Sf9 insect cells infected with rBV-GM-CSF. (E) CD40L expression was detected using rabbit anti-mouse CD40L antibody in Sf9 insect cells infected with
rBV-CD40L. (F) Normal Sf9 insect cells were detected using a mixture of the above-mentioned monoclonal antibodies (200×).
increased the percentage of generation 3 bone marrow cells
compared to the negative control (p = 0.003). We also found
that HTNV VLP-GM-CSF induced the proliferation of bone
marrow cells compared to the HTNV VLPs (p = 0.014). In
contrast, HTNV VLP-CD40L did not induce significant bone
marrow cell proliferation compared to the HTNV VLPs (p =
0.245 for HTNV VLPs and p = 0.412 for the negative control;
Figure 7A).
Then, we analyzed the differentiation of bone marrow cells
using flow cytometry to determine the presence of DCs. We
observed that bone marrow cells that were cultured in the
presence of HTNV VLP-GM-CSF contained significantly higher
numbers of CD11c+ CD11b+ myeloid DCs compared to the
HTNV VLPs and the negative control (p = 0.006 for HTNV
VLP, p = 0.001 for negative control). CD40L incorporated into
the VLPs had no effect on the stimulation of bone marrow
cell differentiation compared to the HTNV VLPs (p = 0.312;
Figure 7B).
Both GM-CSF and CD40L play critical roles in B cell
activation. To determine whether GM-CSF and CD40L
incorporated into HTNV VLPs were capable of activating B
cells, we cultured splenocytes for 4 d in the presence of 20 µg/ml
of VLPs. Then, we analyzed B cell activation by examining the
expression of the activation markers CD69 and B220 using flow
cytometry. We found that the numbers of activated CD69+
B220+ cells increased when splenocytes were cultured with VLPs
relative to the negative control (p = 0.006 for VLP-GM-CSF, p
= 0.003 for VLP-CD40L, and p = 0.012 for HTNV VLPs). We
also found that HTNV VLP-GM-CSF and HTNV VLP-CD40L
increased the number of activated CD69+ B220+ cells compared
to HTNV VLPs (p = 0.014 for VLP-GM-CSF, p = 0.007 for
VLP-CD40L; Figure 7C).
Together, these results demonstrated that GM-CSF and
CD40L incorporated into HTNV VLPs maintained their
biological activities.
GM-CSF and CD40L Incorporated into
HTNV VLPs Induced Proliferation,
Activation, and Switching of DCs In vivo
The numbers of DCs from the splenocytes of immunized mice
were counted by gating CD11c and SSC. As expected, we
found that both HTNV VLP-GM-CSF and HTNV VLP-CD40L
effectively increased the number of DCs compared to the negative
control (p= 0.013 for VLP-GM-CSF, p= 0.009 for VLP-CD40L)
and HTNV VLPs (p = 0.021 for VLP-GM-CSF, p = 0.011 for
VLP-CD40L). We also found that HTNV VLP-GM-CSF and
HTNV VLP-CD40L increased the number of DCs compared
to the vaccine (p = 0.037 for VLP-GM-CSF, p = 0.014 for
VLP-CD40L; Figure 8A).
To determine whether GM-CSF and CD40L incorporated into
HTNV VLPs were capable of activating DCs in the spleen in
vivo, we assessed DC activation by examining the expression of
the activation markers CD86 and CD40 using flow cytometry.
We found that the number of activated DCs from the chimeric
HTNV VLPs increased compared to the negative control (p =
0.009 for VLP-GM-CSF, p = 0.003 for VLP-CD40L) and HTNV
VLPs (p = 0.012 for VLP-GM-CSF, p = 0.007 for VLP-CD40L).
We also found that HTNV VLP-GM-CSF and HTNV VLP-
CD40L increased the number of activated DCs compared to the
vaccine (p= 0.034 for VLP-GM-CSF, p= 0.017 for VLP-CD40L;
Figure 8B).
Because the DC1 population expressed CD8a-
CD11b+CD11c+ as their specific surface markers, and the
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FIGURE 2 | Confocal laser scanning images of the Sf9 insect cells coinfected with rBVs. (A) Sf9 insect cells coinfected with rBV-M, rBV-S, and rBV-CD40L.
(B) Normal Sf9 insect cells. (C) Sf9 insect cells coinfected with rBV-M, rBV-S, and rBV-GM-CSF. (D) Normal Sf9 insect cells (600×). HTNV GP expression was
detected using mAb Gn-4 (Gn-specific) and the FITC-conjugated goat anti-mouse antibody was used as a secondary antibody. CD40L expression was detected
using a rabbit anti-mouse CD40L antibody and the Cy3-conjugated goat anti-rabbit antibody was used as a secondary antibody. GM-CSF expression was detected
using a rat anti-mouse GM-CSF antibody and the Cy3-conjugated goat anti-rat antibody was used as a secondary antibody.
DC2 population expressed CD8a+CD11b-CD11c- as their
specific surface markers, we analyzed the switching of DC by
examining the expression of the CD8a, CD11b and CD11c+
markers using flow cytometry. The number of DC1 cells (CD8a-
CD11b+ CD11c+) was greater than the number of DC2 cells
in each group (except the negative control). We also found that
HTNV VLP-GM-CSF and HTNV VLP-CD40L could effectively
increase the numbers of DC1 cells compared to HTNV VLPs
(p = 0.006 for VLP-GM-CSF, p = 0.003 for VLP-CD40L;
Figure 8C).
CD40L and GM-CSF Incorporated into
HTNV VLPs Elicited Enhanced Humoral
Immune Responses
The immunized mouse sera were collected individually and used
to detect the titers of GP- or NP-specific antibodies using ELISA
to determine whether HTNVVLP-CD40L and HTNVVLP-GM-
CSF could elicit specific and enhanced immune responses against
the HTNV major antigens GP and NP. The GMT of the mice
immunized with the HTNV VLP against GP and NP were 47.6
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FIGURE 3 | Electron microscopy of VLPs. (A) Electron microscopy of the HTNV VLPs in Sf9 insect cells coinfected with rBV-M and rBV-S. (B) Electron microscopy
of HTNV VLP-GM-CSF in Sf9 insect cells coinfected with rBV-M, rBV-S, and rBV-GM-CSF. (C) Electron microscopy of HTNV VLP-CD40L in Sf9 insect cells coinfected
with rBV-M, rBV-S, and rBV-CD40L. (D) Electron microscopy of purified HTNV VLPs. (E) Electron microscopy of purified HTNV VLP-GM-CSF. (F) Electron microscopy
of purified HTNV VLP-CD40L (80,000×).
FIGURE 4 | Characterization of purified VLPs using SDS-PAGE and Western blot. (A) SDS-PAGE of the purified VLPs. (B) Western blot analysis of the purified
VLPs using Gn-4. (C)Western blot analysis of the purified VLPs using Gc-10. (D)Western blot analysis of the purified VLPs using 1A8. (E)Western blot analysis of the
purified VLPs using rat anti-mouse GM-CSF. (F) Western blot analysis of purified VLPs using rabbit anti-mouse CD40L.
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FIGURE 5 | Characterization of the purified VLPs using immunoelectron microscopy. Purified HTNV VLP-GM-CSF and HTNV VLP-CD40L were stained using
anti-GM-CSF or anti-CD40L antibodies, respectively, and a secondary antibody labeled with 10 nm colloidal gold. (A) Immunoelectron microscopy of purified HTNV
VLP-GM-CSF. (B) Immunoelectron microscopy of purified HTNV VLP-CD40L (80,000×).
FIGURE 6 | Characterization of purified VLPs using coimmunoprecipitation. (A) HTNV VLP-GM-CSF was immunoprecipitated with anti-GM-CSF antibody and
then probed with anti-GP antibody (Gn-4). (B) HTNV VLP-GM-CSF was immunoprecipitated with anti-GP antibody (Gn-4) and then probed with anti-GM-CSF
antibody. (A,B Lanes: 1, protein marker; 2, HTNV VLP-GM-CSF; 3, HTNV VLP-GM-CSF as a positive control without precipitation; and 4, HTNV VLPs as a negative
control) (C) HTNV VLP-CD40L was immunoprecipitated with anti-CD40L antibody and then probed with anti-GP antibody (Gn-4). (D) HTNV VLP-CD40L was
immunoprecipitated with anti-GP antibody (Gn-4) and then probed with anti-CD40L antibody. (C,D Lanes: 1, protein marker; 2, HTNV VLP-CD40L; 3, HTNV
VLP-CD40L as a positive control without precipitation; and 4, HTNV VLPs as a negative control).
and 95.1, respectively; however, the GMT of mice immunized
with the HTNV VLP incorporated with CD40L or GM-CSF
against GP and NP were 113.1 and 269.1 for CD40L and 95.1
and 226.3 for GM-CSF, respectively. The results demonstrated
that the HTNV VLP could enhance immune responses against
the HTNVmajor antigens GP (p= 0.03 for VLP-CD40L and p=
0.031 for VLP-GM-CSF) and NP (p= 0.007 for VLP-CD40L and
p= 0.03 for VLP-GM-CSF) after being incorporated with CD40L
and GM-CSF. We also found that the GMTs of HTNV VLP-
CD40L and HTNV VLP-GM-CSF were not significantly higher
than those of the inactivated hantavirus vaccine group against GP
(80) (p = 0.41 for VLP-CD40L and p = 0.77 for VLP-GM-CSF)
and NP (190.3) (p = 0.21 for VLP-CD40L and p = 0.54 for VLP-
GM-CSF), although the lowest titers of the HTNV VLP-CD40L
andHTNVVLP-GM-CSF groups against GPwere both 80, which
is higher than that of the inactivated hantavirus vaccine group
(40). The GMTs of mice immunized with the HTNV VLP with
added soluble CD40L or GM-CSF against GP andNPwere 80 and
160 for soluble CD40L and 67.3 and 134.5 for soluble GM-CSF,
respectively. The GMTs of the mice immunized with PBS against
GP and NP were extremely low (GMT < 10; Figures 9A,B).
Next, we assessed the neutralizing activity of the induced
antibodies by determining the ability of the serum to neutralize
the live HTNV strain 76–118. The GMT of the neutralizing
antibody from mice immunized with the HTNV VLPs was
33.6; however, the GMT of the neutralizing antibody from
mice immunized with the HTNV VLPs incorporated with
CD40L and GM-CSF were 134.5 and 113.1, respectively. These
results demonstrated that the HTNV VLP could elicit enhanced
neutralizing activity after incorporation with CD40L and GM-
CSF (p = 0.002 for VLP-CD40L and p = 0.011 for VLP-
GM-CSF). We also found that the GMT of the neutralizing
antibody from mice immunized with HTNV VLP-CD40L and
HTNV VLP-GM-CSF were significantly higher than the GMT
of the inactivated Hantavirus vaccine (47.6) (p = 0.007 for
VLP-CD40L and p = 0.032 for VLP-GM-CSF). The GMTs
of the neutralizing antibody from mice immunized with
HTNV VLPs with added soluble CD40L or GM-CSF were
both 47.6, which was similar to the inactivated hantavirus
vaccine group. The GMT of the neutralizing antibody from
mice immunized with PBS was extremely low (GMT < 10;
Figure 9C).
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FIGURE 7 | Flow cytometry characterization of the biological activities of GM-CSF and CD40L incorporated into HTNV VLPs. All the experiments were
repeated four times. (A) Single-cell suspensions of bone marrow cells from C57BL/6 mice were labeled with 1 µM CFSE and cultured in vitro in the presence of 20
µg/ml of VLPs. Four days later, the cells were harvested, and the extent of cellular proliferation was determined using CFSE dilution. Representative flow cytometric
plots are shown. The numbers indicate the percentages of generation 3 (average ± standard error). (B) Single-cell suspensions of bone marrow cells from C57BL/6
mice were cultured in vitro in the presence of 20 µg/ml of VLPs. Four days later, the cells were stained with FITC-conjugated anti-CD11b and PE-conjugated
anti-CD11c antibodies. Representative flow cytometric plots are shown. The numbers indicate the percentages of gated populations in the double-positive quadrant
(average ± standard error). (C) In vitro cultures were set up as described for (B), and the cells were stained with FITC-conjugated anti-B220 and PE-conjugated
anti-CD69 antibodies. Representative flow cytometric plots are shown. The numbers indicate the percentages of gated populations in the double-positive quadrant
(average ± standard error).
Based on these results, we conclude that CD40L and GM-
CSF incorporated into HTNV VLPs elicited enhanced humoral
immune responses.
CD40L and GM-CSF Incorporated into
HTNV VLPs Elicited Enhanced Cellular
Immune Responses
First, we measured cytokine production using ELISPOT assays
as an indicator of cellular immune responses to compare T
cell responses to VLPs. Briefly, CD8-depleted splenocytes from
HTNV VLP-CD40L and HTNV VLP-GM-CSF immunized mice
stimulated with a mixture of purified HTNV NP and GP
exhibited a significantly higher number of IFN-γ spots compared
to the HTNV VLP group (p = 0.007 for VLP-CD40L and p =
0.012 for VLP-GM-CSF). The highest numbers were observed in
the HTNV VLP-CD40L group. We also found that the numbers
of IFN-γ spots from the HTNV VLP-CD40L and HTNV VLP-
GM-CSF groups were higher than those of the inactivated
Hantavirus vaccine group (p = 0.014 for VLP-CD40L and p =
0.017 for VLP-GM-CSF). The number of IFN-γ spots in the
HTNV VLP group with added soluble CD40L or GM-CSF was
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FIGURE 8 | Flow cytometric characterization of the proliferation,
activation and DC switch in the spleens of immunized mice (four mice
per group). (A) Single-cell suspensions of spleens from immunized mice were
gated with SSC and PE-conjugated anti-CD11c antibodies. Representative
flow cytometric plots are shown. The numbers indicate the percentages of
DCs (average ± standard error). (B) Single-cell suspensions of spleens from
immunized mice were stained with FITC-conjugated anti-CD40 and
PE-conjugated anti-CD86 antibodies. Representative flow cytometric plots are
shown. The numbers indicate the percentages of gated populations in the
double-positive quadrant (average ± standard error). (C) Single-cell
suspensions of spleens from immunized mice were stained with
APC-conjugated anti-CD8a, FITC-conjugated anti-CD11b, and PE-conjugated
anti-CD11c antibodies. The figure shows the percentage of DC1
(CD8a-CD11b+CD11c+) and DC2 (CD8a+CD11b− CD11c−) cells in the
spleens of immunized mice. The data are expressed as the average ±
standard error.
not significantly higher than the inactivated Hantavirus vaccine
group. The number of IFN-γ spots in mice immunized with
PBS was extremely low. The results were similar in the CD4-
depleted splenocytes (Figure 10A). The changes in the IL-2 levels
were similar to those observed for IFN-γ (Figure 10B). The IL-
4 and IL-10 levels did not change significantly in any of the
immunization groups (data not shown). Based on these results,
CD40L and GM-CSF incorporated into HTNV VLPs induced
effective IFN-γ and IL-2 responses.
LDH release from HTNV-infected Vero E6 cells targeted by
vaccination-activated splenocytes was measured using a Cytotox
96 non-radioactive cytotoxicity assay kit. The cytotoxicity of
splenocytes from mice immunized with VLPs was enhanced in
accordance with the E/T ratio, which was the most significant
at the 100:1 ratio. Among the experimental groups, splenocytes
from mice immunized with either HTNV VLP-CD40L or with
HTNV VLP-GM-CSF and then stimulated with purified HTNV
NP showed higher specific cytotoxic activity compared to the
HTNV VLP group with E/T ratios of 100:1 (p = 0.0009 for VLP-
CD40L and p = 0.0003 for VLP-GM-CSF), 50:1 (p = 0.0003
for VLP-CD40L and p = 0.0012 for VLP-GM-CSF), and 20:1 (p
= 0.0044 for VLP-CD40L and p = 0.0033 for VLP-GM-CSF).
Additionally, the specific cytotoxic activities were even higher
than those of the vaccine group with E/T ratios of 100:1 (p =
0.0077 for VLP-CD40L and p = 0.0018 for VLP-GM-CSF), 50:1
(p = 0.0001 for VLP-CD40L and p = 0.0019 for VLP-GM-CSF),
and 20:1 (p = 0.0078 for VLP-CD40L and p = 0.0101 for VLP-
GM-CSF). The specific cytotoxic activity of HTNV VLPs with
added soluble CD40L or GM-CSF was not significantly higher
than the vaccine group. In contrast, the non-specific cytotoxicity
in the naive group was extremely weak at E/T ratios of 100:1, 50:1,
and 20:1 (Figure 10C). The results were similar when purified
HTNVGP (Figure 10D) was used for stimulation. Based on these
results, CD40L and GM-CSF incorporated into HTNV VLPs
induced very specific cytotoxic activity.
Based on these findings, we conclude that CD40L and GM-
CSF incorporated into HTNV VLPs elicited enhanced cellular
immune responses.
HTNV VLPs and Chimeric HTNV VLPs
Induced Protective Immunity against HTNV
Challenge in C57BL/6 Mice
The mice were challenged with HTNV 10 d after the final
booster immunization to assess protective immunity. HTNV-
specific antigens in the tissues of mice were first detected after 3
d using ELISA. We found that the HTNV-specific antigens were
detected in the livers, spleens, and kidneys of C57BL/6mice in the
naive group (P/N= 16.05, 7.06, and 6.02, respectively). However,
HTNV-specific antigens were not detected in the livers, spleens,
and kidneys of C57BL/6 mice in any of the experimental groups
or the inactivated Hantavirus vaccine group (Figures 11C,D,F).
HTNV-specific antigens were not detected in other tissues of
C57BL/6 mice in any of the groups (Figures 11A,B,E). These
results indicated that the immunization of C57BL/6 mice with
HTNV VLPs conferred protective immunity against HTNV
challenge.
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FIGURE 9 | Characterization of humoral immune responses elicited by HTNV VLPs incorporated with either GM-CSF or CD40L. The mouse sera were
collected as described in the Section Materials and Methods. The results were expressed as the mean value ± SD of four independent experiments. The horizontal
lines denote the GMT values. VLP-GM-CSF and VLP-CD40L indicate the HTNV chimeric VLPs, VLP+GM-CSF, and VLP+CD40L indicate the HTNV VLPs with either
soluble GM-CSF or CD40L. (A) Anti-GP antibody titers were detected using purified GP. (B) Anti-NP antibody titers were detected using purified NP. (C) Neutralizing
antibody titers were detected by determining the ability of the sera to neutralize the live HTNV 76–118 strain. *p < 0.05 compared to the HTNV VLP group; **p < 0.05
compared to the inactivated hantavirus vaccine group.
FIGURE 10 | Characterization of cellular immune responses elicited by HTNV VLPs incorporated with either GM-CSF or CD40L. The mouse splenocytes
and the CD4 or CD8-depleted splenocytes were collected as described in the Section Materials and Methods. The results are expressed as the mean value ± SD of
four independent experiments. VLP-GM-CSF or VLP-CD40L indicates the HTNV chimeric VLPs, VLP+GM-CSF, or VLP+CD40L indicates the HTNV VLPs with
soluble GM-CSF or CD40L. (A) ELISPOT analysis of IFN-γ secreted by CD4 or CD8-depleted splenocytes. (B) ELISPOT analysis of IL-2 secreted by CD4 or
CD8-depleted splenocytes. (C) Cytotoxicity assay of splenocytes stimulated with NP. (D) Cytotoxicity assay of splenocytes stimulated with GP. *p < 0.05 compared
to the HTNV VLP group; **p < 0.05 compared to the inactivated hantavirus vaccine group.
Using qRT-PCR, we also detected HTNV-specific nucleic
acids in the tissues of immunized C57BL/6 mice after challenge
with HTNV. We found that HTNV-specific nucleic acids were
detected in the livers, spleens and kidneys of C57BL/6 mice in
the naive group, with 211.5-, 29.37- and 29.03-fold amplification,
respectively, relative to the inactivated Hantavirus vaccine group.
However, HTNV-specific nucleic acids were not detected in
the livers, spleens and kidneys of C57BL/6 mice in any of the
experimental groups or the inactivated Hantavirus vaccine group
(Figures 12C,D,F). Moreover, HTNV-specific nucleic acids were
not detected in any other tissues of the C57BL/6 mice in any of
the groups (Figures 12A,B,E). These results were consistent with
the ELISA results.
Taken together, these results demonstrate that HTNV VLPs
and chimeric HTNV VLPs induced protective immunity in
C57BL/6 mice against HTNV challenge.
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FIGURE 11 | ELISA detection of HTNV-specific antigens from the major tissues of immunized C57BL/6 mice after being challenged with HTNV. The
mouse tissues were collected as described in the Section Materials and Methods. The results are expressed as the mean value ± SD of four independent experiments.
VLP-GM-CSF or VLP-CD40L indicates the HTNV chimeric VLPs, VLP+GM-CSF, or VLP+CD40L indicates the HTNV VLPs with soluble GM-CSF or CD40L. (A)
Detection of HTNV-specific antigens in the cerebrum. (B) Detection of HTNV-specific antigens in the heart. (C) Detection of HTNV-specific antigens in the liver. (D)
Detection of HTNV-specific antigens in the spleen. (E) Detection of HTNV-specific antigens in the lungs. (F) Detection of HTNV-specific antigens in the kidneys.
DISCUSSION
This study is the first to demonstrate that membrane-bound
forms of the immunostimulatory molecules GM-CSF and CD40L
could be incorporated into HTNV VLPs in a functionally active
form to enhance immune responses in C57BL/6 mice when
expressed in insect cells coinfected with rBVs expressing HTNV
GP, NP, and GPI-anchored GM-CSF or CD40L. Furthermore,
we demonstrated that these GM-CSF and CD40L molecules
maintained their biological activities when incorporated into
VLPs and that immunization with chimeric HTNV VLPs
protected C57BL/6 mice against HTNV challenge.
In the Case of the Baculovirus Expression
System (BEVS), the MOI, TOI, and CCI were
Used to Regulate VLP Production
In the case of the BEVS, the following three key parameters
were used to regulate VLP production: the MOI (Aucoin
et al., 2006; Mena et al., 2010), the time of infection (TOI;
Palomares et al., 2002), and the cell concentration at the time of
infection (CCI; Maranga et al., 2004). In the present study, the
HTNV VLPs and chimeric HTNV VLPs were produced using
a coinfection strategy. The use of coinfection in this study has
allowed combinatorial choices of the MOI ratios, TOI, and CCI.
We experimented with many different combinations of MOI
ratios, TOI, and CCI (Table 1) to produce the HTNV VLPs and
chimeric HTNV VLPs and finally chose to coinfect Sf9 cells with
rBV-M and rBV-S at an MOI ratio of 1:1 and rBV-M, rBV-
S, and rBV-GM-CSF or rBV-CD40L at a MOI ratio of 1:1:3.
The overall MOI was 20 PFU/cell, the TOI was 1 h after the
inoculation of Sf9 insect cells (early phase), and the CCI was 1
× 107 cells/ml (high concentration). The incorporation of either
GM-CSF or CD40L into HTNV VLPs with a higher MOI of
rBV-GM-CSF or rBV-CD40L would be advantageous. The high
overall MOI and CCI were used to ensure that the peak cell
density was reached when all of the cells were infected and that
every cell was coinfected with all of the rBVs (Wong et al., 1996).
The early TOI was used to ensure sufficient nutrient levels in
the culture medium and determine the cell state that would be
advantageous for increasing VLP production. A late TOI could
be used unless the culture medium was replaced at the time of
infection (Sokolenko et al., 2012). Because the viral infection
was similar to a random Poisson process (Kamen et al., 1996;
Hu and Bentley, 2001; Palomares et al., 2002), we could not
ensure that all of the VLPs produced were correctly assembled
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FIGURE 12 | qRT-PCR detection of HTNV-specific nucleic acids from the major tissues of immunized C57BL/6 mice after being challenged with HTNV.
The mouse tissues were collected as described in the Section Materials and Methods. The results are expressed as the mean value ± SD of four independent
experiments. VLP-GM-CSF or VLP-CD40L indicates the HTNV chimeric VLPs, VLP+GM-CSF, or VLP+CD40L indicates the HTNV VLPs with soluble GM-CSF or
CD40L. (A) Detection of HTNV-specific nucleic acids in the cerebrum. (B) Detection of HTNV-specific nucleic acids in the heart. (C) Detection of HTNV-specific nucleic
acids in the liver. (D) Detection of HTNV-specific nucleic acids in the spleen. (E) Detection of HTNV-specific nucleic acids in the lungs. (F) Detection of HTNV-specific
nucleic acids in the kidneys.
using the above strategies. Increasing the ratio of the correctly
assembled VLPs and purifying these VLPs using sucrose gradient
ultracentrifugation would be beneficial. These results confirmed
that HTNV VLPs and chimeric HTNV VLPs were successfully
produced.
Incorporation of CD40L into HTNV VLPs
Enhanced Their Immunogenicity
The present study demonstrated that the incorporation of
CD40L into HTNV VLPs enhanced their immunogenicity,
as evidenced by the induction of both humoral and cellular
immune responses against HTNV NP and GP in vivo.
The augmented immunogenicity may have resulted from the
enhanced ability of HTNVVLP-CD40L to induce the phenotypic
and functional maturation of DCs. CD40L binding to CD40
on the DCs increases the expression of surface MHC, adhesion
and costimulatory molecules, facilitating antigen processing,
and presentation by MHC class II molecules to CD4+ T cells
(Svensson et al., 1997). IL-12 is upregulated in DCs activated by
CD40L binding (Yellin et al., 1995; Van Kooten et al., 2000), IL-
12 is a cytokine responsible for polarizing CD4+ T cells to adopt
a Th1 phenotype that primarily secretes IFN-γ and IL-2 and
enhancing CD8+ T cell proliferation. Polarizing CD4+ T cells
to adopt a Th1 phenotype generally inhibits the Th2 phenotype
that primarily secretes IL-4 and IL-10 (Pulendran et al., 1999). In
the present study, we found that HTNV VLP-CD40L increased
the numbers of DC1 cells for polarizing CD4+ T cells to adopt
a Th1 phenotype (Figure 8C), we also found that HTNV VLP-
CD40L produced higher levels of IFN-γ and IL-2 compared to
HTNV VLPs; however, the IL-4 and IL-10 levels did not change
significantly in any of the immunization groups (Figures 10A,B).
These results indicate that the incorporation of CD40L into
the HTNV-VLPs enhanced the secretion of IFN-γ and IL-2. In
addition, CD40L-activated DCs and other APCs have the ability
to present exogenous peptides (VLPs) on MHC class I molecules
and increase the stimulation of CD8+ T cell responses. Our
findings also demonstrate that CD40L incorporation into HTNV
VLPs produces strong primary CD4+ Th1 and CD8+ T cell
responses. Other studies that incorporated CD40L into VLPs
to enhance immunogenicity reported similar results (Skountzou
et al., 2007; Zhang et al., 2010). The incorporation of CD40L
into HTNV VLPs also increased the titers of GP- and NP-specific
antibodies and the neutralization antibody. Sufficient amounts
of antigen must be present in secondary lymphoid organs to
stimulate B cells in the marginal zone to induce specific antibody
responses. A single dose of HTNV VLPs was not sufficient to
induce strong humoral immune responses. In contrast, CD40L
may enhance the activation levels of marginal zone APCs by
binding to CD40 on APCs and thus may provide sufficient
activation signals to B cells with a single dose of HTNV VLPs
(Schilizzi et al., 1997). In addition, CD40L-activated Th cells also
facilitate the proliferation and differentiation of B cells. Thus,
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TABLE 1 | Different combinations of MOI ratios, TOI, and CCI used to produce the HTNV VLPs and chimeric HTNV VLPs.
MOI ratios Overall MOI TOI CCI
rBV-M: rBV-S 1:0.1
1:1
1:10
1:1:0.1
40 PFU/cell
20 PFU/cell
10 PFU/cell
1 h after the inoculation of Sf9 insect cells (early phase);
24 h after the inoculation of Sf9 insect cells (late phase)
1× 107 cells/ml (high concentration)
1× 106 cells/ml (medium concentration)
rBV-M: rBV-S: 1:1:1 5 PFU/cell
rBV-CD40L or 1:1:3 1 PFU/cell 1× 105 cells/ml (low concentration)
rBV-GM-CSF 1:1:5
1:1:10
0.1 PFU/cell
Final choice: MOI ratios: rBV-M, rBV-S: 1:1; rBV-M, rBV-S, rBV-CD40L or rBV-GM-CSF: 1:1:3; Overall MOI: 20 PFU/cell; TOI: 1 h after the inoculation of Sf9 insect cells (early phase);
CCI: 1× 107 cells/ml (high concentration).
the titers of GP- and NP specific antibodies and neutralization
antibody induced by HTNV VLP-CD40L were higher relative to
those induced by HTNV VLPs.
Incorporation of GM-CSF into HTNV VLPs
Enhanced Their Immunogenicity
The present study also showed that the incorporation of GM-
CSF into HTNV VLPs enhanced their immunogenicity, as
evidenced by the induction of both humoral and cellular immune
responses against HTNV NP and GP in vivo. Similar to CD40L,
GM-CSF is an important hematopoietic growth factor and
immune modulator that strongly stimulates the proliferation and
maturation of DCs, which are crucial in inducing T cell-mediated
and B cell-mediated responses (Metcalf, 1986; Gasson, 1991).
Moreover, GM-CSF can attract APCs toward the antigens and
allows for possible interactions with APCs to enhance uptake
(Morrissey et al., 1987). We demonstrated that the incorporation
of GM-CSF into HTNV VLPs can induce the proliferation of
bone marrow cells and can generate DCs. The DCs produced
appear to be of myeloid origin (CD11c+, CD11b+), which is
consistent with previous data for GM-CSF-derived DCs.
Incorporation of CD40L and GM-CSF into
HTNV VLPs Significantly Enhanced Their
Immunogenicity over the Inactivated HTNV
Vaccine
Although, we should not ignore the potential capacity of
inactivated HTNV vaccine to protect people from HTNV
infection, our results showed that the incorporation of either
CD40L or GM-CSF into HTNV VLPs significantly enhanced
their immunogenicity over the inactivated HTNV vaccine,
particularly the neutralizing antibody titers and the CD8+ T
cell-mediated immune responses, which should be the primary
aims of anti-HTNV vaccination. The following possibilities may
explain the observed differences between the chimeric HTNV
VLPs and the inactivated vaccine: (i) the inactivated vaccine
used in this study without adjuvant might cause the inactivated
vaccine to induce weak specific immune responses; (ii) VLP
antigens can be produced to present antigens through the
major MHC II exogenous pathway and the MHC I endogenous
pathway, inducing both CD4+ and CD8+ T cell-mediated
immune responses, however, the inactivated vaccine mainly
presents antigens through the MHC II pathway which induces
CD4+ T cell-mediated immune responses. Our results also
showed that the incorporation of CD40L and GM-CSF into
HTNV VLPs significantly enhanced their immunogenicity
over HTNV VLPs with added soluble CD40L or GM-CSF. We
proposed that chimeric HTNVVLPs may efficiently attract APCs
toward the HTNV VLPs and allow for possible interactions with
APCs to enhance uptake. However, we could not ignore the
capacity of the adjuvant from soluble CD40L or GM-CSF because
these molecules facilitated the enhancement of immunogenicity
by HTNV VLPs more efficiently than HTNV VLPs
alone.
The Development of HFRS Animal Models
Has Been an Intense Area of Research
In HFRS vaccine research, animal protection experiments
represent an important indicator of the effectiveness of a vaccine.
The selection of the most appropriate animal model is critical
for animal protection experiments. The development of HFRS
animal models has been intensely researched. Currently, there
are no animal models that reflect the disease manifestations
of severe HFRS. Non-human primates often provide good
models for studying hantaviruses and therefore have been
assessed as potential HFRS models, although with limited
success (Yanagihara et al., 1988; Gowen and Holbrook, 2008).
Several small laboratory animals have been experimentally
infected with HTNV species, resulting in the characterization of
traditional infection and/or acute disease models. Perhaps the
most successful of these potential models involve the infection of
newborn (suckling; McKee et al., 1985; Ebihara et al., 2000) and
juvenile mice (Seto et al., 2012) with HTNV usually producing
the lethal form of the disease depending on the virus strain
and route of infection utilized. However, we are also aware that
newborn and juvenile mice are not immunocompetent and are
not suitable for animal protection experiments with vaccines. In
the present study, we found that HTNV-specific antigens and
nucleic acids could only be detected in the livers, spleens and
kidneys of C57BL/6 mice in naive groups but not in the other
groups 3 days after infection with the HTNV 76–118 strain via
intramuscular injection. Further studies are required to better
understand why the distributions of HTNV-specific antigens
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and nucleic acids were primarily localized in the livers, spleens,
and kidneys rather than other tissues of the C57BL/6 mice.
These observations indicated that C57BL/6mice immunizedwith
VLPs or vaccine were protected from infection with the HTNV
76–118 strain. According to our observations, VLPs may be a
new approach for animal protection experiments for the HTNV
vaccine.
In summary, the results presented in the current study
demonstrated that the immunostimulatory molecules GM-CSF
and CD40L could be incorporated into HTNV VLPs in their
functionally active forms, resulting in the enhancement of the
immunogenicity of HTNV antigens.We found that GM-CSF and
CD40L incorporation into HTNV VLPs induced significantly
high levels of humoral and cellular immune responses and
protected C57BL/6 mice against HTNV challenge. This study
demonstrates that the surfaces of VLPs can be coated with
biologically active molecules and that HTNV VLP-GM-CSF and
HTNV VLP-CD40L could be utilized as a new type of HTNV
vaccine. Further studies are required to better understand the
process of incorporation, to increase the levels of incorporation
into VLPs and determine how this incorporation affects the
immune responses produced.
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